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Reactivation of occult hepatitis B virus infection, following
treatment of refractory rheumatoid arthritis with abatacept
To the Editor: with many apoptotic and ballooned hepatocytes (Fig. 1A). Moder-
ate steatosis was also present. Portal inﬂammatory cell inﬁltra-
tion was mild. Immunohistochemical stain for HBcAg showed
extensive nuclear and cytoplasmic expression in hepatocytes,
indicative of active viral replication (Fig. 1B). Immunohistochem-
ical stain for HBsAg was negative.
The basic medical treatments and laboratory data pertaining
to HBV infection over time are depicted in Fig. 2.
Abatacept is a soluble fusion protein which links the cytotoxic
T-lymphocyte antigen-4 (CTLA-4) extracellular domain to the Fc
region of the IgG molecule. CTLA-4 is an inhibitory T cell receptor,
similar to CD28 in structure, expressed by activated and regula-
tory T cells (Tregs). CTLA-4 is constitutively expressed on CD4+
CD25+ Tregs, and such expression is important for Treg-mediated
A
B
Letters to the EditorAbatacept is a biologic response modiﬁer that is used in the
treatment of refractory rheumatoid arthritis. This agent is not
known to be associated with reactivation of hepatitis B virus
(HBV) infection [1]. We report a patient with occult HBV infec-
tion, who developed severe hepatitis B following treatment
with abatacept.
This 72-year-old woman, with a 30-year history of rheuma-
toid arthritis, was treated up to 2007 with methotrexate
(15 mg/week, orally) and, periodically, with various non-steroidal
anti-inﬂammatory drugs (NSAIDs). Prednisolone was used almost
continuously during the last decade (10 mg daily). The patient
also received the TNFa antagonist adalimumab (40 mg every
other week) for a period of two years, up to September 2009,
due to refractory, severe and progressive debilitating disease.
Before starting adalimumab, she had serologic evidence of occult
chronic HBV infection: negative HBsAg, positive HBcAb, positive
HBsAb, negative HBeAg, and positive HBeAb. Serologic markers
for HCV and HIV infections were negative. During this whole per-
iod, her AST and ALT serum levels remained below the upper lim-
its of normal (ULN). Her rheumatoid arthritis remained resistant
and severe, and abatacept (750 mg/dose, at 0, 2, 4 weeks and
every 4 weeks thereafter) was started in October 2009, with con-
comitant use of prednisolone (10 mg daily) and leﬂunomide
(20 mg daily). At the time, serum HBV DNA was undetectable.
At the start of abatacept treatment, her serologic HBV markers
were exactly the same as before administration of adalimumab,
and her AST/ALT levels were below the ULN. The aminotransfer-
ase levels were routinely checked every three months, and
remained within normal limits (WNL) up to April 2010. In July
2010, ALT was 1.76  ULN and cGT was 1.62  ULN. After two
months, ALT was 2  ULN, and became 2.76  ULN in November
2010. At the time, cGT was 2.92  ULN, and HBV serology
remained unchanged. Abatacept and leﬂunomide were discontin-
ued. Serum HBV DNA was found to be 12,000 IU/ml (COBAS Taq-
Man, analytical sensitivity 6 IU/ml). In January 2011, ALT was
increased to 5  ULN and cGT was 2.44  ULN. The patient was
hospitalized in February 2011, with ALT 11.58  ULN, cGT
4.5  ULN, bilirubin WNL, anti-HBs serum titer 328.4 mIU/ml,
and serum HBsAg barely detectable (2.49 S/N) for the ﬁrst time.
A liver biopsy was performed. Six days after admission, ALT
became 20.7  ULN, cGT 5.7  ULN, and bilirubin 2.2  ULN
(direct bilirubin: 86%). Serum HBV DNA was 437,000 IU/ml (by
the same method), and treatment with tenofovir 300 mg/day
was immediately started. In May 2011, AST, ALT, and cGT were
WNL, under tenofovir treatment. Serum HBV DNA became unde-
tectable in June 2011, four months after initiation of tenofovir
treatment.Histologic examination of the liver biopsy specimen revealed
hepatitis with severe lobular necroinﬂammatory activity and
mild to moderate ﬁbrosis. There was marked spotty necrosis,
Fig. 1. Liver histology. (A) Liver biopsy specimen with marked lobular necro-
inﬂammatory activity. (B) Immunohistochemical stain for HBcAg showing
extensive nuclear and cytoplasmic positivity of hepatocytes. (A, hematoxylin–
eosin, 200; B, streptavidin–biotin, 100.)
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suppression of T cell proliferation. Through the inhibition of the
co-stimulatory signaling of T cells in rheumatoid arthritis,
abatacept has demonstrated clinical efﬁcacy in multiple
trials [1].
Occult HBV infection is characterized by absence of HBsAg and
HBV DNA in the serum; however, low level HBV replication may
persist, and HBV DNA may be found in the liver. HBcAbs, with or
without HBsAb, are detectable in the serum. Immunosuppression
may lead to reactivation of HBV infection in these individuals.
The outcome of a HBV infection varies according to the rigor of
the immune response, a process that is regulated by a number
of molecules, including the cell surface receptor CTLA-4. Some
CTLA-4 haplotypes (1722C, +49G) that lead to the activation
of antiviral T cell responses were found to be associated with
spontaneous clearance of HBV infection, whereas others leading
to a decreased T cell response (i.e. +6230A) were associated with
viral persistence [2]. The CTLA-4 inﬂuences on the natural recov-
ery from HBV infection are consistent with the emerging role of
Tregs, possibly restraining the rigor of the immune response, in
the pathogenesis of HBV liver disease.
In our case, there was a time lag of two months between dis-
continuation of abatacept treatment and ALT ﬂare, suggesting
that reactivation of HBV infection and hepatitis evolved in paral-
lel to gradual T cell immune reconstitution. It is also important to
note that HBV reactivation occurred with HBsAb serum titers
above 300 mIU/ml, a fact consistent with the key role of T cell
functions in HBV immune control. Interestingly, cases of HBV
reactivation due to the anti-CD20 B cell depleting agent ritux-
imab have been described even with HBsAb serum titers of
300–1000 mIU/ml [3], a level considered to confer efﬁcient neu-
tralization of HBsAg and HBV circulating virion particles in the
liver transplant setting. This is due to the fact that B cells not only
produce antibodies, but also provide key co-stimulatory and
cytokine signals for CD4+ cells, thus activating certain T cell
functions.
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Fig. 2. Diagram of treatments and HBV reactivation. Diagram showing the
biological and antiviral treatments as well as the basic laboratory ﬁndings related
to HBV infection status over time.
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